Davide Verotta Mechanistic and Non-mechanistic Drug Dynamics Modeling
|
Janet Wade Miscellaneous regulatory information
|
Roberto Gomeni1, Jean M. Joulia1,2, Frédéric Pinguet 2, Marc Ychou3 and Françoise Bressolle1,2 Circadian Population Pharmacokinetics of 5-Fluorouracil (5-FU) in Patients with Metastatic Colorectal Cancer
|
Gordon Graham1, Leon Aarons1 and Suneel Gupta2 A Bayesian Analysis of Categorical and Count Pharmacodynamic Data
|
Rik C. Schoemaker, Joop M.A. van Gerven & Adam F. Cohen Estimating potency for the Emax-model without attaining maximal effects
|
Silvy Laporte, Pascal Girard, Patrick Mismetti, Sylvie Chabaud What Is The Relevance Of Estimating Inter-Study Variability In Population Pharmacokinetic Meta-Analysis ?
|
Nick Holford Clinical Pharmacology = Disease Progress + Drug Action. The role of clinical trial modelling, simulation and analysis using the population PKPD approach.
|
J.M.LANAO, S.ROMANO, M.M.FDEZ.DE GATTA, M.V.CALVO, D.CABALLERO, A.DOMÍNGUEZ-GIL. Population Pharmacokinetics Of Amikacin In Hematologic Malignant Patients
|
Patrick Mismetti, Silvy Laporte, Pascal Girard, Hervé Decousus Indirect Pharmacodynamic Model With Two Different Markers Of Oral Anticoagulant In Young Healthy Volunteers
|
D. Santos Buelga, G. Frutos, MJ Garcia, MJ Otero, A. Dominguez-Gil Optimization Of A Population Pharmacokinetic Model Of Theophylline In Adult Patients
|
Taright N. (1), Mentré F. (1), Engrand P. (2), Loumaye E. (2), Trinchard-Lugan I. (2), Munafo A. (2). Population Pharmacokinetics of Recombinant Human Luteinising Hormone in Patients
|
M.J. García, D. Santos Buelga, M.J. Otero, B. Blanco, A.C. Falcão, A. Domínguez-Gil Therapeutic Drug Monitoring Of Antiepileptic Drugs; Can We Use TDM Data To Estimate Population Pharmacokinetic Parameters?
|
M. Van Guilder(1), R. Leary(2), A. Schumitzky(1), X.Wang(1), S. Vinks(3), and R. Jelliffe(1). Nonlinear Nonparametric Population Modeling On A Supercomputer.
|
I.Meineke Modelling interoccasion variability after repeated oral drug administration.
|
I. Nestorov, L. Aarons, M. Rowland A population approach to the study of structure-pharmacokinetic relationships: An example with a homologous series of barbiturates
|
Y. Merlé, E. Schmautz, and A Mallet. Assessment Of Two Strategies For Detecting Pharmacodynamic Interactions In The Context Of The NPMLApproach;
|
P. Noertersheuser, S. Ghani, S.Kreis Evaluation of the dose / concentration / response relationship of an antithrombotic acting development drug, performed with NONMEM and P - PHARM
|
U. Wählby*, E. N. Jonsson and M. O. Karlsson A Stepwise Procedure For Interindividual Variability Model Building
|
Williams P, Lane J., Capparelli E., Turkel C. Computer Simulation: A Useful Tool for Trial Dosage Selection
|
Jean-Michel Gries, Pharm.D, Ph.D.(1), Davide Verotta, Ph.D.(2), Lewis B. Sheiner, M.D.(3) Estimation of individual pharmacokinetic parameters in presence of possible non-compliance
|
Rashmi R Shah Limitations of Population Approaches in Regulatory Assessment of New Chemical Entities
|
ML McFadyen(1), SF Marshall (2), PA Milligan(2), DJ Nichols(2) MO Karlsson(3) Clinical versus statistical significance in covariate selection
|
S. F. Marshall(1), P. A. Milligan(1), D. J. Nichols(1) and M. O. Karlsson(2) Do we require the population approach to dose adjust in renal impairment? : A case study with dofetilide
|
Kazimierz H. Kozlowski Semi-Populational Model For Analysis Of Infusable Immunoglobulin-G Pharmacokinetics In VLBW Infants
|
SB Duffull (1), JJ Deely (2). NHG Holford (3). Comparison Of A Semiparametric Method With Nonmem For Population Analysis Of Simulated Data
|
Dave Lunn and Jon Wakefield The analysis of ordinal pharmacodynamic data: applicationto allergy score.
|
Mats O Karlsson and E Niclas Jonsson An Automated Stepwise Covariate Model Building Procedure Within NONMEM
|
Silvy Laporte, Pascal Girard, Patrick Mismetti, Sylvie Chabaud What Is The Relevance Of Estimating Inter-Study Variability In Population Pharmacokinetic Meta-Analysis?
|
J.-L. Steimer, B. Fotteler, R. Gieschke, H.Wiltshire, N. Buss Mixed-effects modeling and simulation of the Dose-AUC relationship of saquinavir in healthy subjects and HIV-positive patients (II)
|
Misba Beerahee, PhD(1) and Mark Sale, MD(2) An integrated population PK-PD model characterising the time course of exposure and clinical endpoints (biochemical, physiological and haemodynamics) for 546C88, a nitric oxide synthase inhibitor, in patients with septic shock.
|
GE Blakey, P McCormack, ADP Dean and N Entwistle An Exploratory Population Pharmacokinetic Analysis Examining The Influence Of Demography and Co-Medication On The Plasma Clearance Of The Anti- Epileptic Remacemide.
|
S Chabaud, P Girard, P Nony , C. Laveille, JP Boissel. PK-PD Model Of Ivabradine, A Bradycardic Agent, And Its Metabolite In Healthy Volunteers
|
Farkad Ezzet Population Pharmacokinetics And Therapeutic Response Of Artemether Following Treatment Of Coartem In Malaria Patients
|
N. Frey (1), M. Dubard (1), J.M.A. Van Gerven (2), and R. Jochemsen (1) Population pharmacokinetics/pharmacodynamics of rilmenidine in 27 hypertensive patients
|
P.McCormack, L. Aarons, N.Yeates, M. Nassim, J. Gardner and M. Russell Pharmacokinetic and pharmacodynamics of AR-C69931MX a novel P2T antagonist in healthy male and female volunteers.
|
Nicolas Simon, Eliane Fuseau, Peter Daley-Yates Fluticasone propionate pharmacokinetics in asthma patients when administered alone or in combination to salmeterol.
|
Georg Hempel, Mats O. Karlsson*, Dinesh P. de Alwis John McNay, Nathalie Toublanc and Hans G. Schaefer Population PK/PD Modelling of 24h-Ambulatory Blood Pressure Data using NONMEM
|
L.Nguyen, P. Variol, B. Tranchand* and C. Puozzo. Population pharmacokinetics of Navelbine: Model set up from phase I data and Validation of a limiting sampling strategy
|
M. Costa*, E. Berno#, G. P. Zara#, C. Della Pepa#, R. Canaparo, M. Eandi# A Non-Parametric Population PK/PD Analysis Of Tolcapone To Predict L-Dopa Plasma Concentrations
|
P. Ghahramani, W.W. Yeo, G.T. Tucker Use of NONMEM to determine the influence of CYP2D6 activity on the pharmacokinetics of amitriptyline and nortriptyline
|